POINT Biopharma Completes Enrollment in Phase 3 Trial of PNT2002 to Treat Prostate Cancer; Shares Rise
POINT Biopharma Completes Enrollment in Phase 3 Trial of PNT2002 to Treat Prostate Cancer; Shares Rise
POINT 生物製藥完成 PNT2002 治療前列腺癌的第三期試驗的註冊;股價上漲
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊